argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference

ARGX 01.06.2025

SERA-AI Powered Highlights
Date of Upcoming Event:2025-01-13
Name of Upcoming Event:43rd Annual J.P. Morgan Healthcare Conference
Full Press ReleaseSEC FilingsOur ARGX Tweets

About Gravity Analytica

Recent News

  • 01.13.2025 - argenx Highlights 2025 Strategic Priorities
  • 01.06.2025 - argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference
  • 12.27.2024 - argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy

Recent Filings

  • 01.13.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
  • 12.27.2024 - EX-99.1 EX-99.1
  • 11.14.2024 - SC 13G/A Statement of Beneficial Ownership by Certain Investors

January 6, 2025Amsterdam, the Netherlands– argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced thatTim Van Hauwermeiren, Chief Executive Officer, will present at the 43rdAnnualJ.P. Morgan Healthcare ConferenceonMonday, January 13, 2025at9:45 a.m. PT.

A live webcast of the presentation may be accessed on the Investors section of the argenx website atargenx.com/investors. A replay of the webcast will be available on the argenx website for approximately 30 days following the presentation.

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker, globally in theU.S.,Japan,Israel, the EU, theUK,ChinaandCanada. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visitwww.argenx.comand follow us onLinkedIn,X/Twitter,Instagram,Facebook, andYouTube.

For further information, please contact:

Media:

Ben Petokbpetok@argenx.com

Investors:

Alexandra Roy(US)aroy@argenx.com

Lynn Elton(EU)lelton@argenx.com

Primary Logo

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com